logo-loader
viewCytoDyn Inc.

CytoDyn hopes to convince FDA & federal gov't to grant approvals with coronavirus patient data

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and diagnostic advisor Dr Bruce Pattersen tell Proactive that recent blood work shows that seven severe coronavirus patients being treated with its drug leronlimab in New York City have shown a significant improvement after seven days in several important biologic markers.

What's more, the duo say three patients in Southern California improved dramatically after being given leronlimab. Pourhassan says he hopes to convince the FDA and federal government to grant approvals with its most recent coronavirus patient data.

Quick facts: CytoDyn Inc.

Price: 2.98 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.44 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

1 week ago

2 min read